Connect Biopharma Hldgs Financials - Benzinga

Connect Biopharma Holdings Ltd

CNTBNASDAQ

Trade with Public

Trade with Public

$1.09

-0.01-0.91%

Dern. MÀJ: Sep 25, 9:28 AM

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Comparer Options Rapport sur les stocks

Connect Biopharma Hldgs Financials

Connect Biopharma Hldgs (CNTB) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Connect Biopharma Hldgs Q2 EPS $(0.27) Beats $(0.31) Estimate, Sales $2.768M Beat $650.000K Estimate

Benzinga Newsdesk

PRO
Connect Biopharma Hldgs Q1 EPS $(0.34) Misses $(0.28) Estimate, Sales $169.000K

Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.28) by 21.43 percent. This is a 78.95 percent decrease over losses of $(0.19) per

Benzinga Newsdesk

PRO
Connect Biopharma Hldgs Q4 EPS $(0.27) Beats $(0.30) Estimate

Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.30) by 10 percent. This is a 68.75 percent decrease over losses of $(0.16) per share

Benzinga Newsdesk

PRO
Connect Biopharma Hldgs Q3 EPS $(0.31) Misses $(0.27) Estimate, Sales $16.000K Down From $1.219M YoY

Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.27) by 14.81 percent. This is a 34.78 percent decrease over losses of $(0.23) per

Benzinga Newsdesk

PRO
Connect Biopharma Hldgs Q2 EPS $(0.23) Misses $(0.22) Estimate, Sales $48.000K Down From $24.116M YoY

Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 185.19 percent decrease over earnings of $0.27 per

Benzinga Newsdesk

PRO
Connect Biopharma Hldgs Q1 EPS $(0.19) Down From $(0.16) YoY

Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.19) per share. This is a 18.75 percent decrease over losses of $(0.16) per share from the same period last year.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved